<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01528098</url>
  </required_header>
  <id_info>
    <org_study_id>PEGPD</org_study_id>
    <nct_id>NCT01528098</nct_id>
  </id_info>
  <brief_title>Comparison of Bowel Cleansing Methods for Colonoscopy in Hospitalized Patients</brief_title>
  <acronym>PEG</acronym>
  <official_title>Efficacy of Bisacodyl Given as Part of a Polyethylene Glycol-based Bowel Preparation Prior to Colonoscopy in Hospitalized Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kangbuk Samsung Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Soon Chun Hyang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyunghee University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanyang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kangbuk Samsung Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two regimens of polyethylene glycol(PEG) plus&#xD;
      bisacodyl versus PEG alone for bowel preparation in hospitalized patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inadequate bowel preparation may lead to a longer colonoscopy, and to an inability to&#xD;
      identify lesions. PEG can provide a rapid orthograde peroral approach to colonic lavage&#xD;
      without producing significant fluid or electrolyte changes. Thus PEG is now commonly used for&#xD;
      bowel preparation. However, large amounts and unsatisfactory taste of PEG solution are&#xD;
      generally poorly tolerated, especially in hospitalized patients who had comorbidity and&#xD;
      restricted ambulation. Recently, a new PEG-based bowel cleansing agents became available. It&#xD;
      combines PEG with a high dose of ascorbic acid or bisacodyl. Although many studies reported&#xD;
      the efficacy of these combined solution for colonoscopy, but efficacy in hospitalized&#xD;
      patients was under-recognized.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy of bowel preparation</measure>
    <time_frame>one day (after colonoscopy)</time_frame>
    <description>Ottawa scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient's compliance and acceptability</measure>
    <time_frame>one day (after injestion of preparation solution)</time_frame>
    <description>acceptability, Visual Analogue Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's compliance and acceptability (2)</measure>
    <time_frame>one day (after injestion of preparation solution)</time_frame>
    <description>stress for ingestion, Stress 0(not) - 4(severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's compliance and acceptability (3)</measure>
    <time_frame>one day (after colonoscopy)</time_frame>
    <description>willingness for re-evaluation, 0(very willing) - 4(some)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Intestine; Complaints</condition>
  <arm_group>
    <arm_group_label>PEG plus bisacodyl</arm_group_label>
    <description>Those who taken PEG 4L + bisacodyl 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG 4L</arm_group_label>
    <description>Those who taken PEG 4L alone</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized patients for colonoscopy in university hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalized patients for colonoscopy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age under 20 years or over 80 years&#xD;
&#xD;
          -  major psychiatric illness&#xD;
&#xD;
          -  known allergy to PEG&#xD;
&#xD;
          -  serious condition- severe cardiac, renal, or metabolic diseases&#xD;
&#xD;
          -  partial colon resection&#xD;
&#xD;
          -  current acute exacerbation of chronic inflammatory bowel disease&#xD;
&#xD;
          -  functional constipation defined by Rome III diagnostic criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Il Park, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kangbuk Samsung Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong Il Park, professor</last_name>
    <phone>82-2-2001-2059</phone>
    <email>diksmc.park@samsung.com</email>
  </overall_contact>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>February 3, 2012</study_first_submitted>
  <study_first_submitted_qc>February 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2012</study_first_posted>
  <last_update_submitted>February 20, 2012</last_update_submitted>
  <last_update_submitted_qc>February 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kangbuk Samsung Hospital</investigator_affiliation>
    <investigator_full_name>Dong Il Park, M.D, Ph.D.</investigator_full_name>
    <investigator_title>Associate professor, Department of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>polyethylene glycol</keyword>
  <keyword>bisacodyl</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

